First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference
May 02 2023 - 7:30AM
First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma”
or the “Company”), a clinical-stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases, announced today the company
will participate in the EF Hutton Inaugural Global Conference being
held May 10-11, 2023 at the Plaza Hotel in New York City.
Details of the events are as follows:
Event: |
EF Hutton Inaugural Global Conference |
Date: |
May 10-11, 2023 |
Registration: |
https://efhconference.com/ |
During the conference, members of the First Wave BioPharma
management team will conduct one-on-one meetings with registered
investors and pharmaceutical companies, showcasing the company’s
business and clinical development strategy, recent corporate
achievements, and anticipated milestones.
About First Wave BioPharma,
Inc.First Wave BioPharma is a clinical-stage
biopharmaceutical company specializing in the development of
targeted, non-systemic therapies for gastrointestinal (GI)
diseases. The Company is currently advancing a therapeutic
development pipeline with multiple clinical stage programs built
around its two proprietary technologies – the biologic adrulipase,
a recombinant lipase enzyme designed to enable the digestion of
fats and other nutrients, and niclosamide, an oral small molecule
with anti-inflammatory properties. First Wave is advancing two
Phase 2 clinical programs built around adrulipase for the treatment
of exocrine pancreatic insufficiency (FW-EPI) in patients with
cystic fibrosis (CF) and chronic pancreatitis (CP). In developing
adrulipase, First Wave is seeking to provide CF and CP patients
with a safe and effective therapy to control EPI that is non-animal
derived and offers the potential to dramatically reduce their daily
pill burden. The company is also advancing multiple programs
involving niclosamide, including FW-UP for ulcerative proctitis and
ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and
FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in
Boca Raton, Florida. For more information
visit www.firstwavebio.com.
Forward-Looking StatementsThis
press release may contain certain statements relating to future
results which are forward-looking statements. It is possible that
the Company’s actual results and financial condition may differ,
possibly materially, from the anticipated results and financial
condition indicated in these forward-looking statements, depending
on factors including whether results obtained in preclinical and
nonclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; whether preliminary or
interim results from a clinical trial will be indicative of the
final results of the trial; whether the Company will be able to
maintain compliance with Nasdaq’s continued listing criteria and
the effect of a delisting from Nasdaq on the market for the
Company’s securities; the size of the potential markets for the
Company’s drug candidates and its ability to service those markets;
the effects of the First Wave Bio, Inc. acquisition, the related
settlement and their effect on the Company’s business, operating
results and financial prospects; and the Company’s current and
future capital requirements and its ability to raise additional
funds to satisfy its capital needs. Additional information
concerning the Company and its business, including a discussion of
factors that could materially affect the Company’s financial
results are contained in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 under the heading “Risk
Factors,” as well as the Company’s subsequent filings with the
Securities and Exchange Commission. All forward-looking statements
included in this press release are made only as of the date of this
press release, and we do not undertake any obligation to publicly
update or correct any forward-looking statements to reflect events
or circumstances that subsequently occur or of which we hereafter
become aware.
For more information:First Wave
BioPharma, Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone:
(561) 589-7020info@firstwavebio.com
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Mar 2024 to Apr 2024
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Apr 2023 to Apr 2024